Claritas Pharmaceuticals, Inc.
CLAZF · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | -$2,055 | $5,790 | $7,750 | $1,674 |
| G&A Expenses | $1,871 | $3,661 | $3,352 | $3,242 |
| SG&A Expenses | $1,871 | $3,661 | $3,352 | $3,242 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $9,696 |
| Operating Expenses | -$184 | $9,451 | $11,102 | $5,093 |
| Operating Income | -$3,276 | -$9,451 | -$11,102 | -$14,499 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,252 | -$16,128 | $17,938 | -$17,364 |
| Pre-Tax Income | -$674 | -$25,834 | $6,836 | -$31,863 |
| Tax Expense | -$4,884 | -$4,622 | -$99 | -$1,856 |
| Net Income | $4,210 | -$21,212 | $6,935 | -$31,863 |
| % Margin | – | – | – | – |
| EPS | 0.16 | -0.95 | 0.55 | -5.2 |
| % Growth | 116.8% | -272.7% | 110.6% | – |
| EPS Diluted | 0.16 | -1 | 0.64 | -5.2 |
| Weighted Avg Shares Out | 26,691 | 22,441 | 12,522 | 6,207 |
| Weighted Avg Shares Out Dil | 26,691 | 22,441 | 10,917 | 6,207 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $225 | $209 | $153 | $16,034 |
| Depreciation & Amortization | -$184 | $9,451 | $11,102 | $19 |
| EBITDA | -$2,792 | -$16,723 | $18,136 | -$15,441 |
| % Margin | – | – | – | – |